Weight Loss, Diabetes Treatments Focus Of FTC's Second Round Of Patent Listing Challenges

 
• By Sue Sutter

The Pink Sheet takes a deep dive into the Federal Trade Commission's second wave of challenges to patents it asserts are improperly listed in the FDA's Orange Book, including patents covering Novo Nordisk's self-injection pens for Saxenda (liraglutide) and Ozempic (semaglutide).

Boxing ring
The FTC's second round of patent listing challenges targets popular self-injectable treatments for weight management and diabetes. • Source: Shutterstock

More from Legal & IP

More from Pink Sheet